



# SZABO SCANDIC

Part of Europa Biosite

## Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!  
See the following pages for more information!



### Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

### Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

### SZABO-SCANDIC Handels GmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

[mail@szabo-scandic.com](mailto:mail@szabo-scandic.com)


[www.szabo-scandic.com](http://www.szabo-scandic.com)

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic)



## PBT434 mesylate

**Cat. No.:** HY-120475A  
**CAS No.:** 2387898-69-1  
**Molecular Formula:** C<sub>13</sub>H<sub>17</sub>Cl<sub>2</sub>N<sub>3</sub>O<sub>5</sub>S  
**Molecular Weight:** 398.26  
**Target:** α-synuclein  
**Pathway:** Neuronal Signaling  
**Storage:** 4°C, sealed storage, away from moisture  
 \* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)



### SOLVENT & SOLUBILITY

#### In Vitro

DMSO : 100 mg/mL (251.09 mM; Need ultrasonic)

	Solvent Concentration	Mass	1 mg	5 mg	10 mg
Preparing Stock Solutions	1 mM		2.5109 mL	12.5546 mL	25.1092 mL
	5 mM		0.5022 mL	2.5109 mL	5.0218 mL
	10 mM		0.2511 mL	1.2555 mL	2.5109 mL

Please refer to the solubility information to select the appropriate solvent.

### BIOLOGICAL ACTIVITY

#### Description

PBT434 methanesulfonate is a potent, orally active and cross the blood-brain barrier α-synuclein aggregation inhibitor. PBT434 methanesulfonate can be used as a iron chelator and modulates transcellular iron trafficking. PBT434 methanesulfonate inhibits iron-mediated redox activity and iron-mediated aggregation of α-synuclein. PBT434 methanesulfonate prevents the loss of substantia nigra pars compacta neurons (SNpc). PBT434 methanesulfonate has the potential for the research of Parkinson's disease (PD)<sup>[1][2]</sup>.

#### In Vitro

PBT434 methanesulfonate (0-20 μM; 3 h) significantly inhibits H<sub>2</sub>O<sub>2</sub> production by iron and significantly reduces the rate of Fe-mediated aggregation of α-synuclein<sup>[1]</sup>.  
 PBT434 methanesulfonate (0-100 μM; 24 h) shows no cytotoxic effects on brain microvascular endothelial cells<sup>[2]</sup>.  
 PBT434 methanesulfonate (20 μM; 24 h) increases the expression of total TfR, Cp protein level in hBMVEC<sup>[2]</sup>.  
 MCE has not independently confirmed the accuracy of these methods. They are for reference only.  
 Cell Cytotoxicity Assay<sup>[2]</sup>

Cell Line:	hBMVEC
Concentration:	1, 10, 20, 50, 100 μM

Incubation Time:	24 h
Result:	Showed no cytotoxic effects on brain microvascular endothelial cells.
Western Blot Analysis <sup>[2]</sup>	
Cell Line:	hBMVEC
Concentration:	20 $\mu$ M
Incubation Time:	24 h
Result:	Increased the expression of total TfR, Cp protein level.

## In Vivo

PBT434 methanesulfonate (30 mg/kg; p.o.; daily for 21 days) significantly preserved neuron numbers in the 6-OHDA intoxication model and shows significantly fewer rotations in the L-DOPA model, significantly reducing SNpc neuronal loss in the MPTP model<sup>[1]</sup>.

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	12 weeks, 25 g, Male C57BL/6 J mice (6-OHDA intoxication model) <sup>[1]</sup>
Dosage:	30 mg/kg
Administration:	P.o.; daily for 21 days (commencing 3 days following induction of lesion)
Result:	Prevented neuronal loss following 6-OHDA, preserving up to 75% of the SNpc neurons remaining (both Nissl and tyrosine hydroxylase (TH) positive neurons) after the initial phase of cell death.
Animal Model:	12 weeks, 25 g, Male C57BL/6 J mice (MPTP model) <sup>[1]</sup>
Dosage:	1, 3, 10, 30, 80 mg/kg
Administration:	P.o.; daily for 21 days (commenced 24 h after induction of lesion)
Result:	Increased the proportion of SNpc cells rescued, increased there was a trend to improved turning behavior, significantly increased varicosity abundance, prevented the decline in levels of the presynaptic marker synaptophysin (SYNP) in a dose-dependent manner.

## REFERENCES

- [1]. Finkelstein DI, et al. The novel compound PBT434 prevents iron mediated neurodegeneration and alpha-synuclein toxicity in multiple models of Parkinson's disease. *Acta Neuropathol Commun.* 2017 Jun 28;5(1):53.
- [2]. Bailey DK, Clark W, Kosman DJ. The iron chelator, PBT434, modulates transcellular iron trafficking in brain microvascular endothelial cells. *PLoS One.* 2021 Jul 26;16(7):e0254794.

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA